These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27453494)

  • 1. Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation.
    Sulaiman I; Lim JC; Soo HL; Stanslas J
    Pulm Pharmacol Ther; 2016 Oct; 40():52-68. PubMed ID: 27453494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BuShenYiQi Formula strengthens Th1 response and suppresses Th2-Th17 responses in RSV-induced asthma exacerbated mice.
    Wang J; Wu J; Kong L; Nurahmat M; Chen M; Luo Q; Li B; Wu X; Dong J
    J Ethnopharmacol; 2014 May; 154(1):131-47. PubMed ID: 24704667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in the clinical development of asthma therapies.
    Staton TL; Choy DF; Arron JR
    Biomark Med; 2016; 10(2):165-76. PubMed ID: 26764286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bu-Shen-Yi-Qi formulae suppress chronic airway inflammation and regulate Th17/Treg imbalance in the murine ovalbumin asthma model.
    Wei Y; Luo QL; Sun J; Chen MX; Liu F; Dong JC
    J Ethnopharmacol; 2015 Apr; 164():368-77. PubMed ID: 25625352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulators and Biologics: Beyond Stepped-Care Therapy.
    Desai M; Oppenheimer J; Lang DM
    Clin Chest Med; 2019 Mar; 40(1):179-192. PubMed ID: 30691711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Targeted Therapies for Uncontrolled Asthma.
    Corren J
    J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gu-Ben-Fang-Xiao decoction attenuates sustained airway inflammation by suppressing ER stress response in a murine asthma remission model of respiratory syncytial virus infection.
    Lu Y; Xu JY; Zhang XH; Zhao X
    J Ethnopharmacol; 2016 Nov; 192():496-509. PubMed ID: 27660012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma.
    Santus P; Radovanovic D
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1083-92. PubMed ID: 27409410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
    Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
    Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent research and developmental strategy of anti-asthma drugs.
    Nagai H
    Pharmacol Ther; 2012 Jan; 133(1):70-8. PubMed ID: 21924291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lebrikizumab for the treatment of asthma.
    Antoniu SA
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1239-49. PubMed ID: 27554950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
    Bel EH; Ten Brinke A
    Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.
    Krug N; Hohlfeld JM; Kirsten AM; Kornmann O; Beeh KM; Kappeler D; Korn S; Ignatenko S; Timmer W; Rogon C; Zeitvogel J; Zhang N; Bille J; Homburg U; Turowska A; Bachert C; Werfel T; Buhl R; Renz J; Garn H; Renz H
    N Engl J Med; 2015 May; 372(21):1987-95. PubMed ID: 25981191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
    Parulekar AD; Kao CC; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New perspectives of childhood asthma treatment with biologics.
    Just J; Deschildre A; Lejeune S; Amat F
    Pediatr Allergy Immunol; 2019 Mar; 30(2):159-171. PubMed ID: 30444939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic and New Therapies in Asthma.
    Tabatabaian F; Ledford DK; Casale TB
    Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.
    Beeh KM; Kanniess F; Wagner F; Schilder C; Naudts I; Hammann-Haenni A; Willers J; Stocker H; Mueller P; Bachmann MF; Renner WA
    J Allergy Clin Immunol; 2013 Mar; 131(3):866-74. PubMed ID: 23384679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoregulatory Effects of Paeoniflorin Exerts Anti-asthmatic Effects via Modulation of the Th1/Th2 Equilibrium.
    Zhang T; Yang Z; Yang S; Du J; Wang S
    Inflammation; 2015 Dec; 38(6):2017-25. PubMed ID: 25971794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.